MDS 2020 | Personalized medicine in Parkinson’s disease

Parkinson’s disease is characterized as a multisystem, multineurotransmitter dysfunction‐related heterogeneous disorder and not a single entity. Oscar Gershanik, MD, Favaloro University, Buenos Aires, Argentina, shares his concerns on how some of the new clinical trials’ approaches do not consider Parkinson’s disease individuality. Additionally, Prof. Gershanik mentions that personalized medicine may be the best way to address Parkinson’s disease treatment. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).